FDA grants priority review for Intellia rare genetic disease therapy
Intellia Therapeutics’ experimental gene-editing treatment for a rare genetic disease has received U.S. FDA priority review status, putting the stock back in focus among investors.
S. Food and Drug Administration granted priority review to its experimental gene-editing treatment for a rare genetic disease. The development comes just days after Cathie Wood’s ARK Invest increased its stake in the company.